



COST-EFFECTIVENESS ANALYSIS OF AMEVIVETM (ALEFACEPT)
IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-
SEVERE PSORIASIS
Iskedjian M1, Barkovsky L1, Desjardins O1,Walker JH2, Dorkalam M3,
Shear N4, Einarson TR4
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada;
2Brock University, St. Catharines, ON, Canada; 3Biogen Idec Canada
Inc, Mississauga, ON, Canada; 4University of Toronto,Toronto, ON,
Canada
OBJECTIVES: Alefacept is a new biological that is effective 
for moderate-to-severe plaque psoriasis. This study evaluated its
cost-effectiveness compared to traditional systemic treatments.
METHODS: A two-year Markov model was developed.
Response was measured using Psoriasis Area and Severity 
Index Score (PASI) 75 and length of remission. Treatment com-
parators were methotrexate, cyclosporine, and phototherapy
(with/without acitretin). Data and resource use were derived
from the literature, expert clinical opinion and a cost of illness
(COI) study. Costs (Canadian dollars) were obtained from stan-
dard published sources. Analyses were conducted from the
Ontario Ministry of Health (MoH) and societal (SOC) perspec-
tives. RESULTS: In the MoH base case, expected costs were
$7,790, $9042, $10,635, $32,859 for methotrexate, photother-
apy, cyclosporine and alefacept, respectively. Response-days
associated with each treatment were 175, 78, 175 and 247 days
respectively. Phototherapy and cyclosporine were both domi-
nated. The incremental cost-effectiveness ratio (ICER) was
$349/response-day ($127,473/response-year) for alefacept over
methotrexate. In the SOC base case analysis, the expected costs
were $11,871, $13,416, $15,010 and $36,510 respectively. 
Phototherapy and cyclosporine were dominated. The ICER was
$343/response-day ($125,281/response-year) for alefacept over
methotrexate. These analyses used PASI 75 scores to measure
clinical outcomes, however, the PASI 50 may be more clinically
meaningful for dermatologists and patients. In the PASI 50 
sensitivity analysis from the MoH perspective, the ICER was
$287/response-day ($104,827/response-year) against methotrex-
ate; results from the SOC perspective were similar. In a sensitiv-
ity analysis, savings also increased over time. Results from PASI
50 over three years were similar to those for PASI 75 after ﬁve
years. CONCLUSION: Alefacept offers incremental beneﬁts
compared to methotrexate, and displays cost-effectiveness in
selected scenarios while cyclosporine and phototherapy were
dominated in all scenarios.
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OBJECTIVES: To examine Number-Needed-to-Treat (NNT)
and compare associated costs of care among treatments for 
moderate-to-severe psoriasis. METHODS: We conducted an
Expert Panel systematic literature review of randomized,
placebo-controlled trials for moderate-to-severe psoriasis. Study
inclusion criteria were designed to minimize bias. Treatments
included traditional oral systemics (acitretin and cyclosporine)
and newer biologics (alefacept, efalizumab, etanercept, inﬂix-
imab). For each treatment, we applied systematic literature
review ﬁndings to calculate NNT (average number of patients
required to achieve one additional treatment success compared
to placebo). Treatment success was deﬁned as 75% improvement
on the Psoriasis Severity Area Index (PASI) or “clear/almost
clear” status per physician global assessment (PGA). We used
October, 2004 US Average Wholesale Drug Prices and 2004
Medicare Reimbursement Rates to estimate annualized total
treatment costs (USD). Costs reﬂected the US managed health
care payer perspective and comprised: medications + treatment
administration (e.g., IV infusion) + monitoring (e.g., laboratory
procedures) + risk-adjusted adverse events costs. RESULTS:
NNT (95% CI) were: acitretin 50mg/day NNT = 2 (1–6); ale-
facept 15mg/week NNT = 5 (3–9); cyclosporine 3 mg/kg/day
NNT = 3 (2–6); efalizumab 1mg/kg/week NNT = 5 (4–9); etan-
ercept 50mg twice weekly NNT = 2 (2–3); inﬂiximab 5mg/kg
weeks zero, two, six and bimonthly thereafter NNT = 1 (1–1).
Estimated annualized total treatment costs were: cyclosporine
$6951; acitretin $13,060; efalizumab $17,999; etanercept
$21,158; inﬂiximab $26,436; and alefacept $27,098. Using
NNT results, we estimated the following annualized costs to
achieve one treatment success: cyclosporine $20,853; acitretin
$26,120; inﬂiximab $26,436; etanercept $42,316; efalizumab
$89,995; and alefacept $135,490. CONCLUSIONS: In an envi-
ronment absent of head-to-head comparative trials, where bur-
geoning demand for newer and more costly treatments contends
with limited health care resources, payors and providers seek
alternative methods to compare safety, efﬁcacy, and costs of
treatment for moderate-to-severe psoriasis. Our NNT analysis
suggests that although newer biologic treatments offer helpful
treatment alternatives, traditional oral systemics may provide
more cost-effective treatment options.
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OBJECTIVE: The impact of psoriasis medication therapy on
costs and patient outcomes in large nationally representative
samples needs further examination. The study examined the
association between factors related to medication use and costs
linked with the treatment of psoriasis in the United States.
METHODS: Longitudinal cohort study using the United 
States Medical Expenditure Panel Survey (MEPS) Database
(1996–2001). Information on health care service utilization,
costs, demographics and clinical patient variables were obtained
from the MEPS dataset. Self-reported health status information
was obtained from the EuroQoL (EQ-5D) used in MEPS. Mul-
tivariate weighted analysis was performed on data for approxi-
mately 333,000 patients (weighted sample size). RESULTS:
Approximately 44% of the psoriasis-speciﬁc health care cost in
patients was accounted by medications alone, with an average
of 3.4 psoriasis prescription reﬁlls annually. Topical corticos-
teroids were used by as many as 57.1% of patients, 30.5% used
other medications, while, 12.4% did not receive any pharmaco-
logical treatment. About 42% of the variance was explained by
the multivariate models examining predictors of health care
costs. Among medication-related factors, increased psoriasis 
prescription reﬁll rates were associated with an increase in 
psoriasis-speciﬁc health care costs (p = 0.009). Increase in fre-
